Retatrutide is an experimental peptide from Eli Lilly that activates the receptors for three hormones: GIP, GLP-1 and glucagon.1,4,5 It is not an approved drug. FDA states that it is not a component of any FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law.2 Published randomized trials report weight loss and lower blood sugar, including a 338-person Phase 2 obesity trial and a 537-person Phase 3 diabetes trial. Several other Phase 3 trials are registered on ClinicalTrials.gov.3,5,6,9 FDA says it has warned companies for marketing retatrutide to consumers, including products falsely labeled as being for research purposes.2
Retatrutide at a glance
What it is
An investigational agonist of the GIP, GLP-1 and glucagon receptors, developed by Eli Lilly and also known as LY3437943.1,5
FDA status
Not FDA-approved. FDA states that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law.2
Human evidence
Randomized trials reported in journals: two Phase 2 trials and one Phase 3 diabetes trial. Other Phase 3 trials are registered.3,4,5,6
Evidence strength
Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned
What is retatrutide?
Retatrutide is an experimental peptide being developed by Eli Lilly and Company, which ClinicalTrials.gov lists as the sponsor of the trial record cited on this profile. It is also known by its development code, LY3437943.1
The published trial reports describe it as a single molecule that activates the receptors for three hormones: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon.4,5
How is retatrutide thought to work?
The 2023 New England Journal of Medicine report describes retatrutide as a triple-hormone-receptor agonist, meaning one molecule that acts on three hormone receptors.3
The sources reviewed here do not establish how much each of the three receptors contributes to the effects reported in trials.3,4,5
What do human studies show?
In the Phase 2 obesity trial, 338 adults with obesity, or overweight with a weight-related condition, were randomized to retatrutide or placebo. At 48 weeks, average body-weight change ranged from −8.7% to −24.2% across the retatrutide groups, compared with −2.1% with placebo.3
In that trial, gastrointestinal events were the most common adverse events, and increases in heart rate peaked at 24 weeks before declining.3
A Phase 2 trial of 281 adults with type 2 diabetes reported changes in HbA1c, a measure of long-term blood sugar, ranging from −0.43 to −2.02 percentage points across the retatrutide groups at 24 weeks, compared with −0.01 for placebo and −1.41 for the active comparator.4
In TRANSCEND-T2D-1, a Phase 3 trial of 537 adults whose type 2 diabetes was not controlled by diet and exercise, HbA1c fell by 1.69 to 1.94 percentage points across the retatrutide groups at 40 weeks, compared with 0.81 with placebo. Gastrointestinal events were common, and 2% to 5% of participants in the retatrutide groups stopped because of adverse events, compared with none on placebo.5
That report recorded two deaths in one retatrutide group, which the authors considered unrelated to study treatment.5
These trials followed participants for 24 to 48 weeks for their main results, which does not show long-term outcomes, rare harms, or what happens after treatment stops.3,4,5
What the evidence base contains
Large randomized human trial A 48-week double-blind, randomized, placebo-controlled Phase 2 trial in 338 adults with obesity, or overweight with a weight-related condition, published in The New England Journal of Medicine.3
Controlled human trial A randomized, double-blind Phase 2 trial with placebo and active comparator groups in 281 adults with type 2 diabetes at 42 U.S. centers, published in The Lancet.4
Large randomized human trial TRANSCEND-T2D-1, a 40-week double-blind, randomized, placebo-controlled Phase 3 trial in 537 adults with type 2 diabetes, published in The Lancet.5
Registered trial without results Phase 3 trials in obesity with cardiovascular disease (NCT05882045) and in obesity with type 2 diabetes or sleep apnea (NCT05929079), listed as completed in registry records updated July 30, 2026. Their results are not part of the sources cited here.6,7
Registered trial without results A Phase 3 trial in people with cardiovascular or chronic kidney disease (NCT06383390), listed as active, not recruiting in its August 24, 2026 registry record.9
No. FDA’s page on unapproved GLP-1 drugs, current as of October 1, 2026, states that retatrutide is not a component of any FDA-approved drug and has not been found safe and effective for any condition.2
The same page states that retatrutide and cagrilintide cannot be used in compounding under federal law.2
FDA says it has warned telehealth companies for marketing unapproved drugs such as retatrutide, including directly to consumers, distributors of active ingredients for selling retatrutide to compounders, and outsourcing facilities for repackaging it.2
FDA also says it has warned companies that sold unapproved drugs containing retatrutide falsely labeled as being for research purposes or not for human consumption, and it urges consumers to avoid these products, which it says are of unknown quality.2
Retatrutide remains in clinical trials. None of the sources reviewed here reports an approval of retatrutide in any country.2,10
Timeline
Results of two Phase 2 trials, in obesity and in type 2 diabetes, are published.3,4
Results of TRANSCEND-T2D-1, a Phase 3 trial in type 2 diabetes, are published in The Lancet.5
FDA’s page on unapproved GLP-1 drugs, which says retatrutide cannot be used in compounding, is updated, as shown by its content-current date.2
What is still unknown?
Whether the weight and blood-sugar results lead to fewer heart attacks, strokes or other long-term complications: the published trials measured weight and HbA1c over 24 to 48 weeks.3,5
What the completed Phase 3 trials found: their results are not part of the sources cited on this page.6,7,8
What is in retatrutide products marketed outside clinical trials, which FDA describes as unapproved and of unknown quality.2
Compare and browse
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Records, reviews and history
Everything PeptideScanner has collected for Retatrutide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Retatrutide are the records PeptideScanner has selected and published, not every registration or paper about Retatrutide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Status brief and reviewed-evidence summary
Evidence questions
Start with the question you have
Open the cited status, reviewed human evidence, unresolved limits, or profile changes.
In clinical trials; not FDA-approved. Published randomized trials, including a Phase 3 diabetes trial, report weight and blood-sugar changes over up to 48 weeks. FDA states that retatrutide has not been found safe and effective for any condition and has warned companies marketing it to consumers.↗↗↗↗↗
Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.
Three selected reports cover early retatrutide studies and the later TRANSCEND-T2D-1 phase 3 diabetes trial. Populations, comparators and primary endpoints differ across the studies.↗↗↗
What the reviewed sources report
Selected trials reported weight reduction and improved glycated hemoglobin. The newer phase 3 diabetes study supports a glycemic effect in its studied population, but these reports do not establish prevention of long-term complications; gastrointestinal adverse events and discontinuations matter.↗↗↗
What remains unresolved?
Do Phase 3 trials confirm durability, rare harms, and clinically important outcomes across more diverse populations?↗↗
How do participant flow, missing outcomes, protocol history and linked corrections affect interpretation of the selected reports?↗↗↗
Three selected reports cover early retatrutide studies and the later TRANSCEND-T2D-1 phase 3 diabetes trial. Populations, comparators and primary endpoints differ across the studies.123
Bottom line from this bounded source set
Selected trials reported weight reduction and improved glycated hemoglobin. The newer phase 3 diabetes study supports a glycemic effect in its studied population, but these reports do not establish prevention of long-term complications; gastrointestinal adverse events and discontinuations matter.123
Reviewed study record
Phase 2 obesity trial
Design
A double-blind, randomized, placebo-controlled Phase 2 trial followed participants for 48 weeks and assessed body-weight change and safety.1
Population
The trial enrolled 338 adults with obesity, or overweight plus at least one weight-related condition.1
Outcomes reported
At 48 weeks, reported mean body-weight change ranged from -8.7% to -24.2% across retatrutide groups, compared with -2.1% for placebo. Gastrointestinal events were the most common adverse events, and heart-rate increases peaked at 24 weeks before declining.1
Limitations
This was a sponsor-funded Phase 2 trial with 48-week follow-up; it was not a long-term cardiovascular-outcomes or rare-harms study.1
Reviewed study record
Phase 2 type 2 diabetes trial
Design
A randomized, double-blind, placebo- and active-comparator-controlled Phase 2 trial evaluated glycated hemoglobin at 24 weeks and body weight at 36 weeks.2
Population
The trial randomized 281 adults with type 2 diabetes and elevated body-mass index at 42 U.S. centers; 275 were included in efficacy analyses.2
Outcomes reported
At 24 weeks, reported glycated-hemoglobin changes ranged from -0.43 to -2.02 percentage points across retatrutide groups, compared with -0.01 for placebo and -1.41 for the active comparator. Reported body-weight change at 36 weeks ranged from -3.19% to -16.94% across retatrutide groups.2
Limitations
The sponsor-funded trial had 36-week follow-up, 79% completed treatment, and 84% of participants were White; those features limit conclusions about durability and generalizability.2
Reviewed study record
TRANSCEND-T2D-1: phase 3 diabetes study
Design
A blinded randomized placebo-controlled trial assessed 40-week glycated hemoglobin change under NCT06354660.3
Population
The trial randomized 537 adults with type 2 diabetes inadequately controlled with diet and exercise alone.3
Outcomes reported
Under the treatment-regimen analysis, HbA1c decreased by 1.69–1.94 percentage points across active groups versus 0.81 with placebo. Gastrointestinal events were common; adverse-event discontinuations occurred in 2–5% of active groups and none of the placebo group.3
Limitations
HbA1c and weight changes do not establish prevention of long-term complications. The report recorded two deaths in one active group, which the authors considered unrelated to study treatment; it reported no severe hypoglycemia.3
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa2301972. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1016/s0140-6736(23)01053-x. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s0140-6736(26)00967-0. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Investigational status remains separate from trial progress
FDA’s September 1, 2026 page states that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law. FDA source ↗
More findings and the sources behind them
Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal. Earlier dated FDA and registry findings remain separately attributed below.
TRIUMPH-1 is marked completed
The August 21 registry record for NCT05929066 reports 2,335 actual participants and April 30, 2026 completion. Its registered outcomes include weight change, sleep-apnea and knee-osteoarthritis subsets. The retrieved record has no posted summary results; completion alone is not an efficacy finding. NCT05929066 ↗
Cardiovascular and kidney outcomes are still being studied
NCT06383390 is active, not recruiting, in its August 24 record. It lists cardiovascular and kidney composite endpoints, estimated enrollment of 10,000, and estimated completion in February 2029. No summary results are posted in the retrieved record. NCT06383390 ↗
The obesity trial’s primary endpoint was at week 24
NCT04881760 enrolled 338 participants without diabetes. The registered primary endpoint is weight change at week 24, even though the treatment period lasted 48 weeks. The later weight result is a different time point. NCT04881760 ↗
The registry analysis excludes some post-discontinuation data
The primary obesity analysis uses participants with baseline and post-baseline measurements and excludes data after study-drug discontinuation. It therefore does not describe the outcome of assigning treatment regardless of whether everyone continued it. NCT04881760 ↗
The diabetes trial has a different endpoint and comparator
NCT04867785 enrolled 281 participants with type 2 diabetes, with placebo and dulaglutide comparator groups. Its primary endpoint was 24-week HbA1c change; weight results should not replace that registered question. NCT04867785 ↗
Rescue treatment changes the diabetes analysis population
The posted HbA1c analysis excludes data after permanent treatment discontinuation or initiation of rescue medication. This qualification belongs alongside effect estimates when comparing the registry with a paper or a different trial. NCT04867785 ↗
What remains to be checked
Reconcile phase 2 registry estimates with primary publications and preserve time points and estimands.
Appraise newer phase 3 reports and follow cardiovascular/kidney outcomes; missing registry results do not imply no publication.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.
183 retrieved · 3 included · 0 excluded · 180 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"Retatrutide"[Title/Abstract] OR "LY3437943"[Title/Abstract]
Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.
The selected newer trials are not a completed screen of this entire title/abstract search. Additional primary, secondary, safety and protocol reports remain to be appraised.
Showing 25 of 183 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 42250575 — include: Selected primary trial report; the abstract and record metadata were read. Inclusion is not completed full-text appraisal. Study families: NCT06354660.
PubMed 37385280 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT04867785.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 37366315 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT04881760.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 42734711 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42722378 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42721492 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42690722 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42688617 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42683980 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42682157 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42673585 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42669023 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42649514 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42630988 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42624955 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42608321 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42603384 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42602523 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42590128 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42568490 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42567543 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42562129 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42559975 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42556625 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42536830 — not screened: Name-query match awaiting clinical eligibility screening.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
1 retrieved · 0 included · 0 excluded · 1 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA 70585 — not screened: Title-name match awaiting identity and document review. P/0336/2024 : EMA decision of 13 September 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for retatrutide (EMEA-003258-PIP02-23)
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
35 retrieved · 0 included · 0 excluded · 35 awaiting a decision · 0 full-text appraisals
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 25 of 35 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT04881760 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06354660 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05916560 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06297603 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05931367 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06260722 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06383390 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05548231 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07165028 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06313528 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06039826 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05882045 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04143802 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06003465 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04823208 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05959096 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06859268 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05929066 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05929079 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07226947 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06808802 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07035093 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05445232 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03841630 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06982859 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Retatrutide?
In clinical trials; not FDA-approved. Published randomized trials, including a Phase 3 diabetes trial, report weight and blood-sugar changes over up to 48 weeks. FDA states that retatrutide has not been found safe and effective for any condition and has warned companies marketing it to consumers.↗↗↗↗↗
The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
Bibliography fields unavailable here for 10 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
27
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Profile publication history and record countsSource records by collection · 27 dated records
We added a plain-language reader guide with cited answers, published trial results from our human evidence review, current ClinicalTrials.gov records, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026), which states that retatrutide cannot be used in compounding.
PeptideScanner retained ClinicalTrials.gov record NCT05936151 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was retatrutide.
PeptideScanner retained ClinicalTrials.gov record NCT06297603 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was retatrutide.
Selected records span July 20, 2024 to November 13, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
PeptideScanner retained ClinicalTrials.gov record NCT06297603 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was retatrutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07232719 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was retatrutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT05936151 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was retatrutide.↗
PubMed lists PMID 42853576 in JAMA as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42849462 in Lancet (London, England) as Journal Article, with publication-date metadata of 2026-10-10 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PeptideScanner retained ClinicalTrials.gov record NCT07035093 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was retatrutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT06383390 at 2026-09-09T19:17:17.103Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was retatrutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT05929066 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was retatrutide.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42567543 at 2026-08-10T10:49:13.603Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2026-08-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 38323122 at 2026-08-10T10:49:06.879Z. PubMed recorded a metadata revision date of 2026-07-31 and an Entrez history date of 2024-02-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained ClinicalTrials.gov record NCT05882045 at 2026-08-10T18:10:03.944Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT05929079 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide.↗